Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
This protects skin cells from damage, which helps slow down the visible signs of aging
What the Research Shows Recent research on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has revealed concerning trends about body composition changes: A 2023 analysis of STEP trial data found that approximately 39% of weight lost on semaglutide was lean body mass 1 Research on tirzepatide showed similar patterns, with 30-40% of total weight loss coming from lean tissue 2 Comparative studies indicate GLP-1 users may lose more muscle than people losing weight through diet and exercise alone 3 For context: if you lose 50 pounds on a GLP-1 medication, 15-20 pounds might be muscle mass
Those who taking semaglutide to treat obesity were more than seven times more likely to receive a diagnosis
10 As shown in FIGURE 3 , exenatide normalizes blood glucose levels by reducing fasting and postprandial glucose concentrations through a variety of mechanisms, including enhanced glucose-dependent insulin secretion, regulation of glucagon secretion, delayed gastric emptying, and decreased food intake due to centrally mediated effects on satiety
Over time, clinical research revealed a powerful secondary benefit: significant, sustained weight loss
.png?sfvrsn=1e7191c0_3)
